secwatch.observer — SEC 8-K summary
======================================

Issuer:     Grace Therapeutics, Inc. (GRCE)
CIK:        0001444192
Form:       8-K
Filed at:   2025-06-25T23:59:59+00:00
Accession:  0001140361-25-023557
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Grace Therapeutics submits NDA for GTx-104 in aSAH; Phase 3 data positive
-------------------------------------------------------------------------

- NDA for GTx-104 (injectable nimodipine) submitted to FDA for aneurysmal subarachnoid hemorrhage.
- Phase 3 STRIVE-ON trial met primary endpoint: 19% reduction in clinically significant hypotension vs oral nimodipine.
- 54% of GTx-104 patients had relative dose intensity ≥95% vs 8% on oral; 29% more favorable functional outcomes at 90 days.
- Submission may trigger exercise of warrants issued in Sept 2023, yielding up to $7.6M gross proceeds.
- GTx-104 has FDA Orphan Drug Designation, providing 7 years U.S. exclusivity if approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444192/000114036125023557/0001140361-25-023557-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444192/000114036125023557/ef20051001_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-023557

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer